Inicio Actualidad

How pharma will have to deal with the renewed NHS in England

The Conservative-Liberal Democrat coalition released a White Paper in July, setting out proposals for the future direction of the Health Service (NHS). It will bring large-scale structural changes to the NHS as well as a renewed focus on patient outcomes and patient choice. The changes are intended to make the healthcare system more clinically led, with decision making devolved to the ‘front line’ (GPs) rather than with managers. Although the Pharmaceutical Industry has broadly welcomed these proposals, it clearly needs to start to engage more with this potential key-actors and should already be seeking relationships with those ‘thought leading’ GPs who may end up leading the GP consortia.

Inteligencia de Political Intelligence

Resumen Semanal